The Cleveland Clinic is beginning a study to assess the feasibility and clinical impact of using targeted sequencing, provided by Foundation Medicine, to guide cancer care for patients with a variety of solid tumors.

The effort intends to recruit 250 patients over one year who have advanced disease representing one of 15 solid tumor types associated with poor prognosis or relatively limited treatment options including colorectal cancers, pancreatic cancers, lung cancers, and triple-negative breast cancer among others.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.